3 documents found, page 1 of 1
Overweight, Obesity, And Cardiovascular Disease In Heterozygous Familial Hyperc...
Elshorbagy, Amany; Vallejo-Vaz, Antonio J.; Barkas, Fotios; Lyons, Alexander R.M.; Stevens, Christophe A.T.; Dharmayat, Kanika I.; Catapano, Alberico L.Background and aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and whether they confer additional risk of ASCVD independent of LDL cholesterol (LDL-C) remains unclear. Methods: Cross-sectional analysis was conducted in 35 540 patients ...
The time is now: Achieving FH paediatric screening across Europe – The Prague D...
Bedlington, Nicole; Abifadel, Marianne; Beger, Birgit; Bourbon, Mafalda; Bueno, Héctor; Ceska, Richard; Cillíková, Kristýna; Cimická, ZdenkaFamilial Hypercholesterolaemia (FH) is severely under-recognized, under-diagnosed and under-treated in Europe, leading to a significantly higher risk of premature cardiovascular diseases in those affected. FH stands for inherited, very high cholesterol and affects 1:300 individuals regardless of their age, race, sex, and lifestyle, making it the most common inherited metabolic disorder and a non-modifiable card...
Paediatric familial hypercholesterolaemia screening in Europe: public policy ba...
Gidding, Samuel S.; Wiegman, Albert; Groselj, Urh; Freiberger, Tomas; Peretti, Noel; Dharmayat, Kanika I.; Daccord, Magdalena; Bedlington, NicolaFamilial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Po...